Neumora Therapeutics, Inc. Common Stock (NMRA)
Neumora Therapeutics, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Watertown, MA, US. The stock last traded at $1.73, up 1.76% on the session, giving a market capitalisation of $320.5M. On trailing twelve-month figures it carries a trailing P/E of -1.30, a net margin of 0.0%. Its beta of 2.78 implies it has historically moved more than the broad market.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Neumora Therapeutics, Inc. Common Stock is most often compared with the following Healthcare names: